139 related articles for article (PubMed ID: 15655409)
1. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Heim M; Scharifi M; Zisowsky J; Jaehde U; Voliotis D; Seeber S; Strumberg D
Anticancer Drugs; 2005 Feb; 16(2):129-36. PubMed ID: 15655409
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
4. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Wilhelm SM; Carter C; Tang L; Wilkie D; McNabola A; Rong H; Chen C; Zhang X; Vincent P; McHugh M; Cao Y; Shujath J; Gawlak S; Eveleigh D; Rowley B; Liu L; Adnane L; Lynch M; Auclair D; Taylor I; Gedrich R; Voznesensky A; Riedl B; Post LE; Bollag G; Trail PA
Cancer Res; 2004 Oct; 64(19):7099-109. PubMed ID: 15466206
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
6. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
7. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
Panka DJ; Wang W; Atkins MB; Mier JW
Cancer Res; 2006 Feb; 66(3):1611-9. PubMed ID: 16452220
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
10. Targeting Raf-kinase: molecular rationales and translational issues.
Caraglia M; Tassone P; Marra M; Budillon A; Venuta S; Tagliaferri P
Ann Oncol; 2006 Jun; 17 Suppl 7():vii124-7. PubMed ID: 16760274
[TBL] [Abstract][Full Text] [Related]
11. BAY 43-9006: preclinical data.
Wilhelm S; Chien DS
Curr Pharm Des; 2002; 8(25):2255-7. PubMed ID: 12369853
[TBL] [Abstract][Full Text] [Related]
12. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
Heim M; Sharifi M; Hilger RA; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):616-7. PubMed ID: 14692718
[No Abstract] [Full Text] [Related]
14. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
15. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Halling T; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
Am J Hematol; 2012 Mar; 87(3):277-83. PubMed ID: 22190165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
